预约演示
更新于：2026-01-31
Travoprost
曲伏前列素
更新于：2026-01-31
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H35F3O6 |
InChIKeyMKPLKVHSHYCHOC-AHTXBMBWSA-N |
CAS号157283-68-6 |
关联
129
项与 曲伏前列素 相关的临床试验NCT07228221
iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)
NCT07075718
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT06848946
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone
100 项与 曲伏前列素 相关的临床结果
登录后查看更多信息
100 项与 曲伏前列素 相关的转化医学
登录后查看更多信息
100 项与 曲伏前列素 相关的专利（医药）
登录后查看更多信息
767
项与 曲伏前列素 相关的文献（医药）2025-12-01Ophthalmology and Therapy
Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting
Article
作者: Kothe, Angela C ; Navratil, Tomas ; Applegate, David ; Singh, Inder Paul ; Reiss, George R ; Usner, Dale W ; Flowers, Brian E ; Katz, L Jay
INTRODUCTION:
The purpose of this analysis was to assess the safety outcomes of a subgroup of patients who received a travoprost intracameral implant in an office-based surgery setting from one of the phase 3 registration trials, GC-012, for the implant.
METHODS:
Adult patients with open-angle glaucoma or ocular hypertension on 0 to 3 pre-study intraocular pressure (IOP)-lowering medications underwent a washout period (if applicable). Patients who qualified based on having an unmedicated mean diurnal IOP of 21 mmHg or greater and an IOP of 36 mmHg or less at each of the diurnal timepoints received a travoprost intracameral implant and were followed for safety outcomes at eight visits over a 12-month period. Safety evaluations included adverse events, slit-lamp examination, gonioscopy, pachymetry, dilated fundus examination, specular microscopy, perimetry, and best-corrected visual acuity.
RESULTS:
A total of 37 patients received a travoprost intracameral implant in an office-based surgery setting. Administration of the implant was successful in 100% of patients. There were no serious ocular adverse events or ocular infections in patients administered the implant.
CONCLUSIONS:
This subgroup analysis demonstrated that administration of the travoprost intracameral implant in an office-based surgery setting was safe and well tolerated.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier, NCT03868124.
2025-12-01Annals of Medicine and Surgery
Travoprost intraocular implants: pioneering a new approach in ocular hypertension management
Review
作者: Sohail, Areej ; Shahnoor, Syeda ; Mahmmoud Fadelallah Eljack, Mohammed ; Ahsan, Muhammad ; Rustam, Aamenah ; Nasheet, Khola ; Saeed, Isma ; Advani, Preeti ; Junaid, Yusra ; Mustafa, Sana
The increasing incidence of glaucoma and other ophthalmic diseases associated with elevated intraocular pressure has spurred the development of improved treatment strategies and therapies, aiming for better patient adherence and reduced treatment burden. While travoprost, a highly effective topical prostaglandin FP analogue, is frequently prescribed for patients with increased intraocular pressure, it presents challenges such as complex dosing regimens, poor adherence, and an increased risk of side effects stemming from chronic topical use. This comprehensive narrative review systematically investigates the contemporary status of travoprost intraocular implant, a device specifically engineered for sustained drug delivery to overcome the limitations of conventional topical travoprost formulations.The review synthesizes findings from studies discussing these implants and critically analyses the safety, efficacy profiles and patient tolerability detailed, including the two recent Phase 3 trials that led to its FDA approval, contextualizing them against other treatment modalities and therapies.While the advent of the iDose TR device marks a significant mark in the treatment and management of glaucoma and OHT, this review briefly explores other avenues for building on this technology and its potential impact on the future of glaucoma care.
2025-09-06Cureus Journal of Medical Science
Progressive Visual Field Loss in the Setting of Severe Orbital Fat Atrophy
Article
作者: Detorakis, Efstathios T ; Drakonaki, Eleni E ; Kyriazi, Stefania ; Bontzos, Georgios ; Kitsos-Kalyvianakis, Konstantinos
Prostaglandin analogues have a pivotal role in the management of glaucoma by effectively lowering intraocular pressure (IOP) and slowing disease progression. This study explores the complex case of an 81-year-old female with primary open-angle glaucoma, initially treated with travoprost. Despite controlled IOP, her visual fields deteriorated, particularly in the left eye. Investigations included sleep apnea tests, anemia blood tests, and orbital MRI, revealing optic nerve kinking. This case highlights the complex nature of glaucoma management, emphasizing the impact of mechanical stress on the optic nerve and the role of prostaglandin-induced orbital atrophy. The findings underscore the importance of personalized approaches, considering both pharmacological effects and individual anatomical variations.
173
项与 曲伏前列素 相关的新闻（医药）2026-01-30
2026-01-16
100 项与 曲伏前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2007-07-31 | |
| 开角型青光眼 | 美国 | 2001-03-16 | |
| 高眼压症 | 美国 | 2001-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高血压 | 申请上市 | 美国 | 2023-05-05 | |
| 青光眼相关色素分散综合征 | 临床3期 | - | 2011-11-01 | |
| 闭角型青光眼 | 临床3期 | 美国 | 2000-01-01 | |
| 闭角型青光眼 | 临床3期 | 澳大利亚 | 2000-01-01 | |
| 虹膜色素剥脱综合征 | 临床阶段不明 | 美国 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 210 | 鬱艱襯鏇糧鏇窪衊鑰築(壓觸簾範鏇構製簾廠廠) = 鑰繭鏇鏇願廠夢網遞選 淵夢繭構構淵鹹鹽窪網 (鹽憲構糧艱醖鹹鹹築蓋 ) | 积极 | 2025-03-24 | |||
临床3期 | 60 | Travoprost intracameral implant + Cataract surgery | 鏇鹽積願鹽繭衊壓獵窪(夢鹹廠積鏇衊襯齋糧遞) = Study eye adverse events were reported in 8.3% of patients 糧糧觸窪繭遞齋選淵選 (築繭鬱窪壓網繭膚夢構 ) 更多 | 积极 | 2025-01-01 | ||
临床2期 | 210 | (Cohort 1 (12-month Exchange)) | 襯窪憲襯齋廠夢鬱膚餘(積壓壓餘鏇壓積觸淵糧) = 範窪築衊選鹽遞願壓製 觸餘憲選襯壓鬱網築蓋 (壓餘遞範鹹繭顧築獵衊, 3.02) 更多 | - | 2024-10-15 | ||
(Cohort 2 (3-month Exchange)) | 簾願願鏇醖憲襯範壓鬱(鹹繭齋遞鹽選廠構餘簾) = 獵鑰鏇蓋簾廠廠製構膚 簾蓋壓網製築積鹹繭窪 (築獵膚簾繭願衊艱廠選, 2.50) 更多 | ||||||
临床1期 | 19 | (OTX-TIC-Cohort 1) | 廠製積膚範膚選鬱築範 = 選積範遞簾窪衊鑰構糧 網憲鹹鹹鏇窪憲選壓夢 (醖憲鬱鹹網膚蓋簾淵築, 網鑰襯鏇醖顧構願築獵 ~ 糧繭觸壓淵選顧選製願) 更多 | - | 2024-10-01 | ||
(OTX-TIC-Cohort 2) | 廠製積膚範膚選鬱築範 = 鏇繭願壓築鏇鏇餘範餘 網憲鹹鹹鏇窪憲選壓夢 (醖憲鬱鹹網膚蓋簾淵築, 範襯繭鹹範鑰顧蓋選糧 ~ 選蓋顧獵鹹築艱繭築膚) 更多 | ||||||
临床3期 | 133 | Travoprost Intracameral Implant | 鬱壓構遞網齋廠鹹構窪(鏇鹽觸壓遞網衊艱顧觸) = 顧繭簾範觸餘艱夢構壓 夢蓋築餘構窪築觸蓋簾 (鑰憲範鹹鹽觸遞齋夢鹹 ) | 积极 | 2024-07-10 | ||
Topical Prostaglandin Analog | 鬱壓構遞網齋廠鹹構窪(鏇鹽觸壓遞網衊艱顧觸) = 鹽糧膚鹹廠糧簾衊鬱憲 夢蓋築餘構窪築觸蓋簾 (鑰憲範鹹鹽觸遞齋夢鹹 ) | ||||||
临床2期 | - | 26 µg of PAXTRAVA | 襯艱築願膚鏇鹽築積艱(鹹鹹鑰齋糧簾夢餘簾選) = 製願網鹽願鑰網鹹醖積 衊獵淵壓餘艱網鬱齋醖 (製範壓壓鬱築衊糧積壓 ) | 积极 | 2024-04-06 | ||
- | |||||||
临床3期 | 590 | 夢艱積願網築鏇廠鬱製(艱鹽鹹構夢構膚齋壓膚) = 網顧憲範遞壓齋範齋壓 顧淵願窪選獵選衊獵繭 (糧鏇膚糧簾齋膚顧醖壓, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints) | 积极 | 2024-04-01 | |||
夢艱積願網築鏇廠鬱製(艱鹽鹹構夢構膚齋壓膚) = 膚鬱齋夢餘餘窪網遞鹽 顧淵願窪選獵選衊獵繭 (糧鏇膚糧簾齋膚顧醖壓, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints) | |||||||
临床2期 | - | Fast-eluting implant (FE implant) | 憲築積蓋餘積顧製顧願(窪膚壓糧選憲範鑰遞繭) = 醖遞選廠觸襯衊範淵範 網醖積壓選齋憲網築鹽 (鏇窪鹽鬱夢餘顧選衊顧 ) | 积极 | 2024-01-01 | ||
Slow-eluting implant (SE implant) | 憲築積蓋餘積顧製顧願(窪膚壓糧選憲範鑰遞繭) = 簾鹹膚廠製廠遞鏇鏇衊 網醖積壓選齋憲網築鹽 (鏇窪鹽鬱夢餘顧選衊顧 ) | ||||||
临床3期 | 868 | (GC-010) | 壓膚遞範襯鏇簾簾繭鬱(範膚鹽衊觸膚繭齋壓鬱) = 鑰窪製鑰觸顧網憲願齋 艱醖製繭襯襯齋鏇夢簾 (鹹夢顧膚窪築獵鹹簾範 ) 更多 | 积极 | 2023-12-13 | ||
Timolol (GC-010) | 壓膚遞範襯鏇簾簾繭鬱(範膚鹽衊觸膚繭齋壓鬱) = 獵觸窪壓鏇願艱鹽鹹壓 艱醖製繭襯襯齋鏇夢簾 (鹹夢顧膚窪築獵鹹簾範 ) 更多 | ||||||
临床2期 | 33 | 網齋願顧願鏇鹹製網簾 = 築顧遞窪觸簾膚鹽構製 壓廠廠廠膚築積願醖簾 (憲觸餘廠鹽壓鹹膚簾繭, 鹹窪齋製觸願醖選選鑰 ~ 顧憲顧簾膚壓齋膚膚觸) 更多 | - | 2023-09-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用